Sinil Pharmaceutical Co. Ltd (012790) — Capital Reinvestment Ratio
Sinil Pharmaceutical Co. Ltd (012790) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩2.62 Billion) in capital expenditures (₩213.15 Million). See 012790 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Sinil Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Sinil Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 11 annual periods. Check cash flow reinvestment rate of Sinil Pharmaceutical Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Sinil Pharmaceutical Co. Ltd from 2014 to 2024. For live market cap and broader valuation context, see market cap of Sinil Pharmaceutical Co. Ltd.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.37x | ₩22.69 Billion | ₩8.47 Billion | ▼ -56.2% |
| 2023 | 0.85x | ₩15.15 Billion | ₩12.92 Billion | ▲ +25.1% |
| 2022 | 0.68x | ₩13.69 Billion | ₩9.33 Billion | ▲ +109.7% |
| 2021 | 0.33x | ₩11.16 Billion | ₩3.63 Billion | ▼ -59.1% |
| 2020 | 0.80x | ₩11.06 Billion | ₩8.80 Billion | ▲ +0.6% |
| 2019 | 0.79x | ₩12.31 Billion | ₩9.73 Billion | ▼ -12.8% |
| 2018 | 0.91x | ₩9.19 Billion | ₩8.33 Billion | ▼ -16.2% |
| 2017 | 1.08x | ₩8.67 Billion | ₩9.38 Billion | ▲ +409.1% |
| 2016 | 0.21x | ₩12.09 Billion | ₩2.57 Billion | ▼ -65.0% |
| 2015 | 0.61x | ₩9.56 Billion | ₩5.80 Billion | ▲ +152.7% |
| 2014 | 0.24x | ₩9.33 Billion | ₩2.24 Billion | — |